<DOC>
	<DOC>NCT01699737</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.</brief_summary>
	<brief_title>Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This is a randomized, double-blind, double-dummy, placebo and active-controlled (glimepiride), multi-center, parallel-group study to investigate the effect of JTT-851 on HbA1c and other ancillary efficacy parameters and to assess the safety, tolerability, and pharmacokinetics of JTT-851 in inadequately-controlled treatment-naïve or metformin-treated type 2 diabetic patients.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Males and females with type 2 diabetes, 1870 years of age at Visit 1 Managing diabetes with diet and exercise only or currently being treated with a stable dose of metformin (at least 1500 mg/day) Glycosylated hemoglobin at Visit 1 between 7.5% and 10.0%, if on metformin and between 7.5% and 10.9%, if without treatment Body mass index (BMI) ≥ 23.0 kg/m^2 and ≤ 45.0 kg/m^2 at Visit 1 Females who are pregnant or breastfeeding Known medical history or presence of type 1 diabetes or acute metabolic diabetic complications, unstable or rapidly progressing retinopathy, nephropathy or neuropathy Acute coronary syndrome or uncontrolled hypertension Does not meet all diet or previous/concomitant medication restriction criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Diabetes</keyword>
</DOC>